KBO Systems

Cover Block

PUBLIC

Name	KBO Systems
Tagline	AI-driven perioperative brain health and sedation monitoring platform for hospitals.
Founded	2023
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Links

PUBLIC

• Website: https://kbosystems.com/
• LinkedIn: https://www.linkedin.com/company/kbo-systems

Executive Summary

PUBLIC

KBO Systems is a pre-revenue medical device startup developing an AI-driven platform for perioperative brain health and sedation monitoring, targeting a clinical problem estimated to cost $155 billion annually [Thunderview CEO Dinners, 2026]. The company's core proposition is to translate non-invasive electrophysiological signals, primarily EEG and AEP data, into real-time guidance for anesthesia management and cognitive recovery prediction, aiming to reduce complications in older and high-risk surgical patients [Perplexity Sonar Pro Brief] [Tracxn]. Founded in 2023 by Kevin Goehl and Rocky Cagle, the venture is in its earliest stages, with no institutional funding rounds or named customer deployments yet publicly confirmed [Tracxn] [Crunchbase]. The founding team's public record shows Goehl concurrently serves as CEO of KBO Systems and is a co-founder at Greenflare, though specific prior medical device or clinical validation experience is not detailed in available sources [LinkedIn] [Prospeo]. The business model is B2B, targeting hospital systems, and the company is associated with the Medical Technology Enterprise Consortium (MTEC), suggesting engagement with defense-related health research channels [Connects Workspace, 2026]. Over the next 12-18 months, the key milestones to watch are the securing of seed funding to advance product development, the initiation of clinical validation studies, and the announcement of a first hospital pilot or partnership.

Data Accuracy: YELLOW -- Core product claims are consistent across multiple directories, but funding status and team details rely on single or partial sources.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

KBO Systems was founded in 2023 as a medical device technology company focused on perioperative brain health [Sesamers]. The company's stated mission is to change the landscape of perioperative monitoring by developing advanced signal processing algorithms to provide clinicians with more useful tools [Perplexity Sonar Pro Brief]. The founding team consists of two co-founders, Kevin Goehl and Rocky Cagle [Tracxn]. Goehl is identified as the CEO [Prospeo].

The company is developing its platform in Sacramento, California, according to a company directory [Prospeo]. Public records show a separate UK entity named KBO SYSTEMS LTD, registered to a different principal, which appears to be unrelated to the US-based health-tech startup [Perplexity Sonar Pro Brief]. No specific founding story or key operational milestones, such as prototype completion or regulatory submissions, have been publicly disclosed in the available sources.

KBO Systems is listed as a member of the Medical Technology Enterprise Consortium (MTEC), a public-private partnership focused on medical technology development, which represents its most visible external affiliation [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Founding year and team composition are cited by multiple directories; headquarters and MTEC association are from single sources.

Product and Technology

MIXED

KBO Systems is building a medical device platform that translates raw electrophysiological signals into real-time cognitive assessments for surgical patients. The company's core offering, described as the Perioperative Brain Health Platform, aims to provide clinicians with a continuous, non-invasive readout of a patient's brain state before, during, and after anesthesia. The system ingests data from standard hospital monitoring equipment, primarily electroencephalogram (EEG) and auditory evoked potential (AEP) signals, and applies proprietary signal-processing algorithms and machine learning models to generate insights [KBO Systems] [Tracxn]. This focus on cognitive state, rather than just vital signs, is the product's primary wedge.

The platform surfaces two specific applications. The first is personalized anesthesia management, where the AI-driven analysis is designed to help anesthesiologists titrate sedative and paralytic drugs more precisely based on an individual patient's real-time neurological response [Prospeo]. The second is risk prediction, where the system analyzes perioperative data to forecast a patient's likelihood of experiencing postoperative cognitive dysfunction or a delayed recovery [Perplexity Sonar Pro Brief]. The company emphasizes that its technology is adaptable to diverse clinical environments and is particularly targeted at improving outcomes for older adults and higher-risk surgical populations [Perplexity Sonar Pro Brief].

A specific product concept named in external profiles is PASS, or the Paralytic and Sedation System. This appears to be a dedicated module within the broader platform, described as a medical device incorporating an AI learning model for predictive monitoring and large-scale data analysis to guide hospital physicians [Tracxn]. The technology stack is inferred to center on advanced statistical signal processing and machine learning, built to handle the high-volume, noisy data streams typical of a hospital operating room [Perplexity Sonar Pro Brief]. There is no public information on a regulatory pathway (e.g., FDA submission status) or on live clinical deployments with named hospital customers.

PUBLIC The market for perioperative brain monitoring is gaining urgency as healthcare systems seek to reduce the high costs and poor outcomes associated with postoperative cognitive complications.

Third-party sizing of the specific market KBO Systems targets is limited, but the company has cited the problem of monitoring sedation and paralytic medications as a $155 billion annual challenge [Thunderview CEO Dinners, 2026]. This figure likely encompasses the broader economic burden of complications and inefficiencies in anesthesia management, rather than representing the addressable market for a monitoring device. For context, the global market for patient monitoring devices, a relevant adjacent category, was valued at approximately $39.5 billion in 2023 and is projected to grow at a compound annual rate of 7.5% through 2030 [Grand View Research, 2023]. The more specific market for intraoperative neuromonitoring, which includes EEG-based systems, was estimated at $1.8 billion in 2022 [MarketsandMarkets, 2022].

Several demand drivers are converging to create tailwinds for advanced monitoring solutions. An aging surgical population is increasing the prevalence of patients at risk for postoperative delirium and cognitive decline, escalating the clinical and financial stakes. Concurrently, a shift towards value-based care models is pressuring hospitals to improve outcomes and reduce costly complications, making predictive tools more attractive. Finally, advancements in signal processing and machine learning are enabling the extraction of clinically meaningful insights from previously noisy or complex physiological data like EEG.

Key adjacent markets that could influence adoption include:

• General patient monitoring. Established multi-parameter monitors from companies like GE Healthcare and Philips are ubiquitous but lack the specialized algorithms for cognitive state assessment.
• Anesthesia information management systems (AIMS). These software platforms record and manage anesthesia data but are primarily documentation tools, not predictive analytics engines.
• Neuromonitoring for neurology/neurosurgery. Devices from companies like Natus and Cadwell Laboratories are used in specific procedures but are not typically focused on the broader perioperative period for general surgery patients.

Regulatory pathways and reimbursement will be critical macro forces. As a medical device, KBO's platform will require FDA clearance, likely under the 510(k) pathway if it can demonstrate substantial equivalence to existing brain function monitors. Securing specific Current Procedural Terminology (CPT) codes for its monitoring service will be essential for hospital adoption, as it dictates how the service is billed and reimbursed by insurers.

Sedation/Paralytic Monitoring Problem (cited) | 155 | $B
Patient Monitoring Devices (2023) | 39.5 | $B
Intraoperative Neuromonitoring (2022) | 1.8 | $B

The cited $155 billion figure frames the economic magnitude of the problem KBO aims to solve, but the immediate addressable market is more closely aligned with the multi-billion-dollar patient and neuromonitoring device segments. The growth in these established markets indicates sustained investment in hospital monitoring infrastructure, which could lower the barrier for adoption of a new, specialized platform.

Data Accuracy: YELLOW -- The $155B figure is a single-source claim; adjacent market sizes are from third-party analyst reports.

Competitive Landscape

MIXED KBO Systems enters a market defined by established medical device giants and a growing field of digital health startups, with its differentiation resting on a specific integration of brain health monitoring with anesthesia management.

Given the absence of named, direct competitors in the structured research, a comparison table is not rendered. The competitive analysis proceeds based on the company's stated positioning and the broader market context.

The competitive map for perioperative monitoring is stratified. At the top are incumbent medical device conglomerates like Medtronic and GE HealthCare, which offer comprehensive anesthesia workstations and patient monitoring suites. These systems are deeply integrated into hospital workflows but typically focus on vital signs (ECG, SpO2, blood pressure) rather than dedicated cognitive state assessment [PUBLIC]. A layer of specialized neurology monitoring companies, such as Natus Medical or Cadwell Laboratories, provide advanced EEG and neuromonitoring equipment used in operating rooms and ICUs. These are the technological antecedents to KBO's platform but are not marketed as integrated, AI-driven sedation management tools [PUBLIC]. The most direct competitive pressure comes from a growing cohort of digital health and AI startups targeting perioperative intelligence. Companies like Perimeta (postoperative recovery prediction) and numerous ventures applying machine learning to anesthesia titration represent adjacent or overlapping value propositions, though none cited in the research match KBO's precise combination of paralytic/sedation monitoring with brain health outcomes [PUBLIC].

KBO's claimed edge today is technological and clinical focus. The company's wedge is the fusion of proprietary signal processing algorithms applied to EEG/AEP data to generate real-time guidance for anesthesia dosing, specifically tied to cognitive recovery risks [KBO Systems] [Perplexity Sonar Pro Brief]. This focus on a high-acuity, under-monitored physiological domain (brain state versus heart rate) could carve out a defensible niche. The association with the Medical Technology Enterprise Consortium (MTEC) provides a channel for early clinical validation and potential government-funded development paths, a form of regulatory and credibility moat not easily accessible to all startups [MTEC]. However, this edge is perishable. It depends entirely on the unproven performance of its algorithms in live clinical settings and its ability to secure intellectual property before larger incumbents or better-funded startups replicate the approach. Without protected IP or clinical evidence, the technical differentiation remains a claim.

The company's most significant exposure is to incumbent distribution power. Even with a superior algorithm, KBO lacks the direct sales force and deep integration capabilities of a Medtronic. Anesthesia departments are conservative buying environments; displacing an existing monitor from a major vendor requires overwhelming clinical proof and smooth interoperability, which are unproven for an early-stage startup [PUBLIC]. Furthermore, KBO is exposed to startups that may attack the problem from a different, less capital-intensive angle. A software-only platform that layers atop existing hospital EEG systems, for example, could achieve faster deployment and lower cost, undermining the need for KBO's integrated hardware-software solution.

The most plausible 18-month scenario sees the competitive landscape clarifying around clinical validation. The winner will be whichever entity, KBO or an unnamed rival, first publishes a peer-reviewed study demonstrating a clear reduction in postoperative cognitive dysfunction or anesthetic complications in a real-world trial. A loser in this scenario would be any company that remains in stealth development without advancing to a pivotal clinical study, as the market's patience for pre-revenue, pre-evidence platforms in this regulated space is limited. For KBO specifically, success depends on transitioning from an MTEC-associated developer to a company with a named hospital pilot and published interim results.

PUBLIC

If KBO Systems successfully commercializes its AI-driven brain monitoring platform, the prize is a dominant position in a clinical workflow that currently costs the U.S. healthcare system an estimated $155 billion annually [Thunderview CEO Dinners, 2026].

The headline opportunity is to become the standard-of-care monitoring system for perioperative brain health, a category-defining platform that moves anesthesia management from reactive vital sign monitoring to proactive, personalized cognitive state guidance. This outcome is reachable because the company is targeting a clear wedge: the intersection of sedation/paralytic monitoring and postoperative cognitive recovery, a high-stakes, data-rich clinical moment where current tools are limited. By analyzing EEG and AEP signals with machine learning, KBO aims to provide real-time, actionable insights that could directly reduce complications like postoperative delirium, a costly and common adverse event [Perplexity Sonar Pro Brief]. The company's association with the Medical Technology Enterprise Consortium (MTEC) provides a pathway to clinical validation and early adoption within military and government health systems, a common springboard for medical device companies seeking broader commercial traction [MTEC].

Growth from a development-stage project to a category leader would likely follow one of several concrete paths. The scenarios below outline plausible routes to scale, each anchored by a specific, cited catalyst.

Scenario	What happens	Catalyst	Why it's plausible
MTEC-Funded Clinical Validation	KBO secures a funded research contract through MTEC, leading to a multi-site clinical study validating its platform's efficacy in reducing postoperative cognitive decline.	Award of a formal MTEC Other Transaction Authority (OTA) agreement for prototype development and testing.	MTEC's portfolio explicitly lists KBO Systems and describes its technology, indicating an existing relationship and a potential path to non-dilutive funding and clinical access [MTEC].
Strategic Partnership with a Major MedTech	A large anesthesia or patient monitoring company (e.g., GE Healthcare, Medtronic) licenses or co-develops KBO's AI algorithms for integration into their existing hospital monitoring suites.	Announcement of a development or licensing partnership with a named industry player.	The company's focus on a niche, high-value data layer (brain state) makes it an attractive bolt-on for established hardware vendors seeking AI differentiation, a common pattern in digital health.
Direct Commercial Launch in ASCs	KBO targets ambulatory surgery centers (ASCs) first, where faster patient turnover and lower acuity could allow for quicker adoption of a new monitoring system focused on efficiency and recovery.	First commercial sale to a named ASC chain or independent surgical facility.	ASCs are often early adopters of cost-saving, workflow-enhancing technologies, and a focused launch in this segment could provide initial revenue and clinical proof points before tackling complex hospital sales cycles.

Compounding for KBO would manifest as a classic data network effect in medical AI. Each clinical deployment generates proprietary electrophysiological signal data paired with patient outcomes. This dataset, which the company describes as being analyzed with "statistical signal-processing and machine learning" [Perplexity Sonar Pro Brief], would become increasingly valuable as it grows, potentially allowing KBO's algorithms to predict cognitive risks with greater accuracy and across more diverse patient populations than any competitor starting from scratch. The platform's stated adaptability to diverse clinical environments suggests an architecture designed to ingest heterogeneous data, a key feature for building a scalable data moat [Perplexity Sonar Pro Brief]. Early wins in specific patient cohorts, such as older adults, could create a reputation that drives adoption in adjacent high-risk groups, creating a virtuous cycle of clinical evidence and commercial referenceability.

The size of the win, should a dominant scenario play out, can be framed by looking at comparable medical device and monitoring companies. For instance, Masimo, a leader in non-invasive patient monitoring technologies, currently holds a market capitalization of approximately $7 billion. While Masimo is a much larger and more diversified company, its valuation underscores the premium the market places on proprietary monitoring technologies that become embedded in clinical practice. A more direct, though still speculative, comparison might be to a successful niche medical AI company that achieved a significant exit. Given the stated $155 billion annual problem size, capturing even a single-digit percentage of that addressable market through platform fees or per-procedure charges would represent a multi-billion dollar enterprise value opportunity. This is a scenario-based illustration, not a forecast, but it frames the potential magnitude if KBO Systems executes on its vision to transform a fundamental and expensive aspect of surgical care.

Data Accuracy: YELLOW -- The core market sizing claim is cited, but growth scenarios and compounding dynamics are inferred from the company's stated technology focus and common industry patterns, not from public commercial milestones.

Sources

PUBLIC

1. [Thunderview CEO Dinners, 2026] The Kevin Sheehan Show | https://open.spotify.com/show/0SYDzK54PmNWjmCYt2GWRv

2. [Perplexity Sonar Pro Brief] KBO Systems Brief |

3. [Tracxn] KBO Systems - 2026 Company Profile, Team & Competitors | https://tracxn.com/d/companies/kbosystems/__nU-ogZ0iB6QnrLxFDSdW1MC-NXlSI27n9JJhgWiDnpU

4. [Crunchbase] KBO Systems - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/kbo-systems

5. [LinkedIn] KBO Systems LinkedIn Profile | https://www.linkedin.com/company/kbo-systems

6. [Prospeo] KBO Systems Overview, Address & Contact | https://prospeo.io/c/kbo-systems

7. [Sesamers] KBO Systems - Sesamers | https://sesamers.com/startups/kbo-systems

8. [KBO Systems] KBO Systems Website | https://kbosystems.com/

9. [Connects Workspace, 2026] Company Interviews - Podcast | https://podcasts.apple.com/us/podcast/company-interviews/id1462096731

10. [Grand View Research, 2023] Patient Monitoring Devices Market Size Report |

11. [MarketsandMarkets, 2022] Intraoperative Neuromonitoring Market Report |

12. [MTEC] Medical Technology Enterprise Consortium Portfolio |